AT1-receptor antagonism in hypertension: what has been learned with irbesartan?

Détails

ID Serval
serval:BIB_74208AC98170
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Titre
AT1-receptor antagonism in hypertension: what has been learned with irbesartan?
Périodique
Expert Review of Cardiovascular Therapy
Auteur(s)
Waeber B., Burnier M.
ISSN
1477-9072
Statut éditorial
Publié
Date de publication
05/2003
Volume
1
Numéro
1
Pages
23-33
Langue
anglais
Résumé
Irbesartan is a long-acting angiotensin II antagonist acting specifically at the level of the Type 1-receptor subtype (AT1-receptor). This compound lowers blood pressure dose-dependently in hypertensive patients and has a placebo-like tolerability. The antihypertensive efficacy of irbesartan is greatly enhanced by the coadministration of a diuretic, and fixed-dose combinations of irbesartan and hydrochlorothiazide are now available. Irbesartan-based treatment appears especially effective for high-risk patients, such as those with diabetes, renal disease and cardiac hypertrophy. In patients with Type 2 diabetes, irbesartan delays the development of nephropathy as well as the progression of renal failure. Irbesartan may have antiatherosclerotic properties beyond those expected from blood pressure lowering per se: this AT1-blocker decreases the vascular oxidative stress and prevents the procoagulant as well as the pro-inflammatory effects of angiotensin II. Irbesartan given alone or in combination with a diuretic therefore represents a rational approach to treat hypertensive patients.
Mots-clé
Angiotensin II Type 1 Receptor Blockers, Antihypertensive Agents, Biphenyl Compounds, Blood Pressure, Humans, Hypertension, Tetrazoles
Pubmed
Création de la notice
25/01/2008 13:56
Dernière modification de la notice
03/03/2018 18:20
Données d'usage